🔗 Share this article

Chancellor Rachel Reeves has announced she is preparing "focused steps to deal with cost of living challenges" in the upcoming financial statement.

Speaking to media outlets, she noted that reducing price rises is a joint task of both the administration and the Bank of England.

The United Kingdom's price growth is expected to be the highest among the G7 developed nations this year and the following year.

Potential Utility Bill Interventions

It is understood the administration could intervene to lower energy bills, for example by reducing the present 5% level of value-added tax applied on energy supplies.

An additional approach is to reduce some of the policy costs presently added to bills.

Fiscal Constraints and Expert Expectations

The administration will obtain the next report from the independent fiscal watchdog, the OBR, on the start of the week, which will reveal how much scope there is for such actions.

The view from the majority of experts is that Reeves will have to declare tax increases or expenditure reductions in order to meet her declared debt limits.

Previously on the same day, calculations showed there was a £22 billion deficit for the chancellor to fill, which is at the lower end of projections.

"There's a shared task between the central bank and the government to bear down further on some of the sources of price increases," the Chancellor stated to the BBC in the US capital, at the conferences of the International Monetary Fund and World Bank.

Tax Commitments and Global Issues

While much of the attention has been on expected tax rises, the chancellor said the most recent figures from the OBR had not altered her commitment to election pledges not to raise rates on income tax, sales tax or social security contributions.

She attributed an "unpredictable global environment" with growing geopolitical and commercial issues for the fiscal revenue measures, probably to be targeted on those "wealthiest."

International Economic Tensions

Referring to apprehensions about the UK's commercial links with China she said: "The UK's national security always take priority."

Recent declaration by Chinese authorities to strengthen trade restrictions on critical minerals and other resources that are crucial for high-technology production led US President Donald Trump to threaten an further 100% tariff on goods from the Asian country, increasing the possibility of an full-scale commercial conflict between the two economic giants.

The US Treasury Secretary called China's move "economic coercion" and "a international production control attempt."

Inquired about considering the American proposal to join its conflict with China, the Chancellor said she was "extremely troubled" by China's actions and urged the Beijing authorities "to avoid restrictions and restrict access."

She said the move was "harmful for the world economy and causes additional obstacles."

"I believe there are areas where we need to address Chinese policies, but there are also valuable prospects to sell into Chinese markets, including banking sector and other areas of the economy. We've got to get that equilibrium correct."

The Treasury chief also affirmed she was cooperating with international partners "on our own essential resources plan, so that we are more independent."

Health Service Medicine Costs and Investment

Reeves also acknowledged that the price the National Health Service spends on drugs could increase as a result of current negotiations with the Trump administration and its pharmaceutical firms, in return for lower tariffs and capital.

Some of the biggest global pharmaceutical manufacturers have said in recent statements that they are either delaying or scrapping investments in the UK, with several blaming the modest returns they are obtaining.

Recently, the Science Minister said the cost the NHS pays for drugs would need to go up to halt companies and drug research funding departing from the United Kingdom.

The Chancellor told media: "We have seen as a result of the pricing regime, that medical research, recent pharmaceuticals have not been available in the UK in the manner that they are in other continental states."

"The objective is to make sure that patients receiving treatment from the NHS are can receive the top critical treatments in the world. And so we are reviewing these issues, and... seeking to attract additional investment into the UK."